The landscape of selection in 551 Esophageal Adenocarcinomas defines genomic biomarkers for the clinic

Citations Over Time

Abstract

Abstract Esophageal Adenocarcinoma (EAC) is a poor prognosis cancer type with rapidly rising incidence. Our understanding of genetic events which drive EAC development is limited and there are few molecular biomarkers for prognostication or therapeutics. We have accumulated a cohort of 551 genomically characterised EACs (73% WGS and 27% WES) with clinical annotation and matched RNA-seq. Using a variety of driver gene detection methods, we discover 77 EAC driver genes (73% novel) and 21 non-coding driver elements (95% novel), and describe mutation and CNV types with specific functional impact. We identify a mean of 4.4 driver events per case derived from both copy number events and mutations. We compare driver mutation rates to the exome-wide mutational excess calculated using Non-synonymous vs Synonymous mutation rates (dNdS). We observe mutual exclusivity or co-occurrence of events within and between a number of EAC pathways (GATA factors, Core Cell cycle genes, TP53 regulators and the SWI/SNF complex) suggestive of important functional relationships. These driver variants correlate with tumour differentiation, sex and prognosis. Poor prognostic indicators (SMAD4, GATA4) are verified in independent cohorts with significant predictive value. Over 50% of EACs contain sensitising events for CDK4/6 inhibitors which are highly correlated with clinically relevant sensitivity in a panel EAC cell lines and organoids.

Related Papers

• → Mutation rates among RNA viruses(1999)1,141 cited
• → The GENCODE exome: sequencing the complete human exome(2011)63 cited
• → Clinical Exome Performance for Reporting Secondary Genetic Findings(2014)35 cited
• → The current landscape of clinical exome and genome reanalysis in the U.S.(2024)2 cited
• → Exome Sequencing in Mendelian Disorders(2010)1 cited